Folate, antifolates, and folate analogs in pediatric oncology

Investigational New Drugs

Volumn 14, Issue 1, 1996, Pages 101-111

  Hum, Martina C ^a   Kamen, Barton A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antifolate; DHFR; Methotrexate

Indexed keywords

AMINOPTERIN; AMINOPTERIN DERIVATIVE; EDATREXATE; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLIC ACID DERIVATIVE; LOMETREXOL; METHOTREXATE; RALTITREXED; TRIMETREXATE;

ACUTE LYMPHOCYTIC LEUKEMIA; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0029836092     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00173686     Document Type: Review

References (15)

1. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA: Temporary remissions in acute leukemia in children produced by folie acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). New England Journal of Medicine 238:787-793, 1948
2. Franklin AL, Belt M, Stokstad ELR, Jukes TH: Biological studies with 4-amino-10-methylpteroyl-glutamic acid. Journal of Biological Chemistry 177:621-629, 1949
3. Goldin A, Venditti JM, Humphreys SR, Mantel N: A quantitative comparison of the antileukemic effective-ness of two folic acid antagonists in mice. Journal of the National Cancer Institute 15:1657-1664, 1955
4. Chu E, Takimota CH: Antimetabolites. In De Vita VT, Hellman S, Rosenburg SA (eds) Cancer: Principles & Practice of Oncology, 4th Ed, pp 358-374. Philadelphia, Lippincott, 1993
5. Matherly LH, Barlowe CK, Goldman ID: Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. Cancer Research 46:588-593, 1986
6. Fabre I, Fabre G, Goldman ID: Polyglutamylation, an important element in methorexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cell in vitro. Cancer Research 44:3190-3195, 1984
7. Allegra CJ, Fine RL, Drake JC, et al.: The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells: evidence for direct inhibition of purine synthesis. Journal of Biological Chemistry 261:6478-6486, 1986
8. Allegra CJ, Hoang K, Yeh GC, et al.: Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cancer cells as a principal mode of metabolic inhibition by methotrexate. Journal of Biological Chemistry 262:13520-13526, 1987
9. Takimoto CH, Allegra CJ: New antifolates in clinical development. Oncology 9:649-659, 1995
10. Chu E, Takimoto CH, Voeller D, Grem JL, Allegra CJ: Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 32:4756-4760, 1993
11. Hartwell LH, Kastan MB: Cell cycle control and cancer. Science 266:1821-1828, 1994
12. Slansky JE, Li Y, Kaelin WG, Farnham PJ: A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Molecular and Cellular Biology 13(3):1610-1618, 1993
13. Sholar PW, Baram J, Seither R, et al.: Inhibition of folate-dependent enzymes by 7-OH-methotrexate. Biochemical Pharmacology 37:3531-3534, 1988
14. 2 rescue in delayed MTX-elimination due to renal failure. Pediatric Hematology and Oncology 12:471-477, 1995
15. 2 in rhesus monkeys. Journal of Clinical Oncology 10(8): 1359-1364, 1992